Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2025-04-11 00:00:00 ET · period of report 2025-04-01 · accession 0000897069-25-000787 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-11 | 2025-04-01 | PCSA | Young David | Pres. Research, Development, Dir | F - Tax | $0.41 | -5,345 | 217.3K | -2% | -$2,191 | |
| 2025-04-11 | 2025-04-01 | PCSA | Young David | Pres. Research, Development, Dir | M - OptEx | — | +17.3K | 222.7K | +8% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | F | D | 5,345 | $0.41 | 217,332 | D | — | — | |
| 2 | Common | Common Stock | 2025-04-01 | M | A | 17,272 | — | 222,677 | D | — | — | (F1) Distribution of vested restricted shares. |